Kyowa Kirin Co., Ltd

Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.